Pagari PharmaTech
Private Company
Funding information not available
Overview
Pagari PharmaTech is a private, early-stage CDMO focusing on the drug delivery sector for small molecules, primarily in oral solid and liquid dosage forms. The company provides integrated services spanning research and development, analytical testing, technology transfer, and clinical-to-commercial scale manufacturing, targeting pharmaceutical clients seeking US-based manufacturing and regulatory support. While still in an early-revenue phase, Pagari is actively building its market presence through industry events and emphasizes its regulatory readiness and scalable capacity as key differentiators. Its success will depend on its ability to secure and execute client projects in a highly competitive CDMO landscape.
Technology Platform
Integrated CDMO service platform for oral dosage forms, encompassing formulation development, analytical testing, scalable cGMP manufacturing, and regulatory support from concept to commercialization.
Opportunities
Risk Factors
Competitive Landscape
Pagari competes in a fragmented but crowded CDMO market. It faces competition from large public CDMOs (e.g., Catalent, Lonza), other US-focused private CDMOs, and generic drug manufacturers with contract service arms. Its differentiation is its integrated 'concept-to-commercialization' promise for oral doses and emphasis on being a client-centric, US-based partner.